Microglia in Glioblastomas: Molecular Insight and Immunotherapeutic Potential

Sabrina Nusraty,Ujwal Boddeti,Kareem A. Zaghloul,Desmond A. Brown

DOI: https://doi.org/10.3390/cancers16111972

2024-05-23

Cancers

Abstract:Glioblastoma (GBM) is one of the most aggressive and devastating primary brain tumors, with a median survival of 15 months following diagnosis. Despite the intense treatment regimen which routinely includes maximal safe neurosurgical resection followed by adjuvant radio- and chemotherapy, the disease remains uniformly fatal. The poor prognosis associated with GBM is multifactorial owing to factors such as increased proliferation, angiogenesis, and metabolic switching to glycolytic pathways. Critically, GBM-mediated local and systemic immunosuppression result in inadequate immune surveillance and ultimately, tumor-immune escape. Microglia—the resident macrophages of the central nervous system (CNS)—play crucial roles in mediating the local immune response in the brain. Depending on the specific pathological cues, microglia are activated into either a pro-inflammatory, neurotoxic phenotype, known as M1, or an anti-inflammatory, regenerative phenotype, known as M2. In either case, microglia secrete corresponding pro- or anti-inflammatory cytokines and chemokines that either promote or hinder tumor growth. Herein, we review the interplay between GBM cells and resident microglia with a focus on contemporary studies highlighting the effect of GBM on the subtypes of microglia expressed, the associated cytokines/chemokines secreted, and ultimately, their impact on tumor pathogenesis. Finally, we explore how understanding the intricacies of the tumor-immune landscape can inform novel immunotherapeutic strategies against this devastating disease.

oncology

What problem does this paper attempt to address?

The paper attempts to address the issue of exploring the role of microglia in glioblastoma (GBM) and their potential as targets for immunotherapy. Specifically, the paper focuses on the following points:

1. **Interaction between microglia and GBM cells**: The paper discusses how microglia communicate with GBM cells and influence the tumor microenvironment (TME). In particular, it explores both pro-tumor and anti-tumor pathways.

2. **Different phenotypes of microglia (M1 and M2)**: The M1 phenotype has pro-inflammatory effects, while the M2 phenotype has anti-inflammatory and pro-repair effects. The paper analyzes the different roles of these two phenotypes in GBM progression.

3. **Current and past clinical trials**: The paper reviews clinical trials targeting microglia, summarizes the experiences of successes and failures, and points out possible future research directions.

4. **Novel immunotherapy approaches**: The paper explores new methods to regulate immune responses and inhibit tumor progression by targeting microglia, and proposes some unexplored but potentially promising targets.

Overall, the paper aims to gain a deeper understanding of the complex roles of microglia in GBM in order to discover new therapeutic strategies.